Juvaris reports strong Ph I trial flu vaccine adjuvant

Juvaris BioTherapeutics, a US biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and  cancer, has reported positive results from a Phase I trial of its lead  compound, JVRS-100, as an adjuvant for influenza vaccines.

Results from the randomized, double-blind, controlled trial demonstrated  positive effects of the JVRS-100 adjuvant co-administered with a  commercial influenza vaccine compared to vaccine alone. Increased  antibody responses measured by serum hemagglutination inhibition and  neutralizing antibody titers were observed in subjects receiving  JVRS-100 and vaccine versus vaccine alone in study participants 28 days  post-vaccination.